ArticleApplied biochemistry and biotechnology2025
Shikonin Modulates the NOD2/CARD9 Pathway to Ameliorate Ulcerative Colitis Through Inhibiting M1 Macrophage Polarization.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Given the critical involvement of intestinal macrophages in ulcerative colitis (UC) pathogenesis and Shikonin's (SHK) established anti-inflammatory properties, this study investigated whether SHK inhibits macrophage proinflammatory (M1) polarization in UC and elucidated its downstream mechanisms. Dextran sulfate sodium (DSS)-induced UC model in mice was treated with SHK by gavage, and the therapeutic effect of SHK was evaluated by observing the changes in body weight, colon length, and Disease Activity Index (DAI) in mice. The pathological changes of colon tissue were observed by HE staining, and tight junction (TJ) proteins and inflammatory cytokines in colon tissue were detected. In vitro experiments were conducted to observe the inhibitory effect of SHK intervention on M1 macrophage polarization using LPS/IFN-γ-induced RAW264.7 cell model. Immunofluorescence, RT-qPCR, and Western blot were used to detect changes in NOD2 and CARD9 levels. SHK treatment significantly ameliorated murine colitis, evidenced by reduced DAI, attenuated DSS-induced colon histopathology, and preserved TJ integrity. SHK downregulated colonic expression of macrophage activation markers (F4/80), M1 polarization markers (iNOS, MCP-1), and pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), while elevating anti-inflammatory mediators (IL-10, Arg1). In LPS/IFN-γ-stimulated RAW264.7 macrophages, SHK consistently suppressed M1 polarization markers/pro-inflammatory mediators (TNF-α, IL-6, MCP-1, iNOS) while enhancing M2 markers (IL-10, Arg1, CD206, Ym1). Mechanistically, SHK inhibited the NOD2/CARD9 pathway in both in vivo and in vitro models. Crucially, NOD2/CARD9 overexpression attenuated SHK's therapeutic effects in murine colitis and blocked its suppression of M1 polarization in vivo and in vitro. This study demonstrates that SHK alleviates UC by inhibiting NOD2/CARD9-mediated macrophage M1 polarization, revealing a novel therapeutic mechanism for UC management.
Indexed as
Identifiers
41148551What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.